Modern approaches to glioblastoma therapy
Glioblastoma (GBM) is the most malignant and the most common primary tumor of the central nervous system. During the last several years GBM has been classified and managed according to the World Health Organization (WHO) criteria which subdivide it into primary and secondary GBM. As it is suggested,...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
ANO "Perspective of oncology"
2023-03-01
|
| Series: | Южно-Российский онкологический журнал |
| Subjects: | |
| Online Access: | https://www.cancersp.com/jour/article/view/192 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849244465966874624 |
|---|---|
| author | N. S. Kuznetsova S. V. Gurova A. S. Goncharova E. V. Zaikina M. A. Gusareva M. S. Zinkovich |
| author_facet | N. S. Kuznetsova S. V. Gurova A. S. Goncharova E. V. Zaikina M. A. Gusareva M. S. Zinkovich |
| author_sort | N. S. Kuznetsova |
| collection | DOAJ |
| description | Glioblastoma (GBM) is the most malignant and the most common primary tumor of the central nervous system. During the last several years GBM has been classified and managed according to the World Health Organization (WHO) criteria which subdivide it into primary and secondary GBM. As it is suggested, GBM originates from glial cells and has a diffuse growth pattern, but its etiology and pathophysiology are poorly investigated up to date. Its rapid progression and anatomical location in the brain often limits the effectiveness of therapeutic interventions. Despite all scientific and technological advances, GBM remains an incurable disease with a median survival of approximately 18 months. Standard treatment options involving maximal safe resection of the tumor followed with radiotherapy and chemotherapy do not provide satisfactory Results.Better understanding of the molecular pathology of GBM and its associated signaling pathways has opened up possibilities for new treatments for newly diagnosed and relapsing tumors. A multitargeted therapeutic approach using compounds capable of inhibiting more than one specific molecular target is a promising alternative to conventional therapies.Currently, specialists study such innovative treatment options as small molecule inhibitors aimed at signaling pathway disruptions, immunotherapy, including checkpoint inhibitors, oncolytic vaccines, CAR T-cell therapy, and drug delivery systems. In terms of an innovative approach, the elaboration of targeted drug delivery systems is of particular interest, since this strategy looks the most promising due to its ability to increase the bioavailability and effectiveness of both standard and newly tested agents. This review discusses results of preclinical and clinical studies of innovative therapeutic approaches, their advantages and disadvantages. An interdisciplinary approach is expected to be able to combine the results of cutting-edge research in this area and to provide novel promising therapeutic strategies for patients with GBM. |
| format | Article |
| id | doaj-art-c976457eb0934116bf3272fea26a0c78 |
| institution | Kabale University |
| issn | 2686-9039 |
| language | Russian |
| publishDate | 2023-03-01 |
| publisher | ANO "Perspective of oncology" |
| record_format | Article |
| series | Южно-Российский онкологический журнал |
| spelling | doaj-art-c976457eb0934116bf3272fea26a0c782025-08-20T03:59:09ZrusANO "Perspective of oncology"Южно-Российский онкологический журнал2686-90392023-03-0141526410.37748/2686-9039-2023-4-1-6119Modern approaches to glioblastoma therapyN. S. Kuznetsova0S. V. Gurova1A. S. Goncharova2E. V. Zaikina3M. A. Gusareva4M. S. Zinkovich5National Medical Research Centre for OncologyNational Medical Research Centre for OncologyNational Medical Research Centre for OncologyNational Medical Research Centre for OncologyNational Medical Research Centre for OncologyNational Medical Research Centre for OncologyGlioblastoma (GBM) is the most malignant and the most common primary tumor of the central nervous system. During the last several years GBM has been classified and managed according to the World Health Organization (WHO) criteria which subdivide it into primary and secondary GBM. As it is suggested, GBM originates from glial cells and has a diffuse growth pattern, but its etiology and pathophysiology are poorly investigated up to date. Its rapid progression and anatomical location in the brain often limits the effectiveness of therapeutic interventions. Despite all scientific and technological advances, GBM remains an incurable disease with a median survival of approximately 18 months. Standard treatment options involving maximal safe resection of the tumor followed with radiotherapy and chemotherapy do not provide satisfactory Results.Better understanding of the molecular pathology of GBM and its associated signaling pathways has opened up possibilities for new treatments for newly diagnosed and relapsing tumors. A multitargeted therapeutic approach using compounds capable of inhibiting more than one specific molecular target is a promising alternative to conventional therapies.Currently, specialists study such innovative treatment options as small molecule inhibitors aimed at signaling pathway disruptions, immunotherapy, including checkpoint inhibitors, oncolytic vaccines, CAR T-cell therapy, and drug delivery systems. In terms of an innovative approach, the elaboration of targeted drug delivery systems is of particular interest, since this strategy looks the most promising due to its ability to increase the bioavailability and effectiveness of both standard and newly tested agents. This review discusses results of preclinical and clinical studies of innovative therapeutic approaches, their advantages and disadvantages. An interdisciplinary approach is expected to be able to combine the results of cutting-edge research in this area and to provide novel promising therapeutic strategies for patients with GBM.https://www.cancersp.com/jour/article/view/192glioblastomananoparticlesimmunotherapysmall-molecule inhibitors |
| spellingShingle | N. S. Kuznetsova S. V. Gurova A. S. Goncharova E. V. Zaikina M. A. Gusareva M. S. Zinkovich Modern approaches to glioblastoma therapy Южно-Российский онкологический журнал glioblastoma nanoparticles immunotherapy small-molecule inhibitors |
| title | Modern approaches to glioblastoma therapy |
| title_full | Modern approaches to glioblastoma therapy |
| title_fullStr | Modern approaches to glioblastoma therapy |
| title_full_unstemmed | Modern approaches to glioblastoma therapy |
| title_short | Modern approaches to glioblastoma therapy |
| title_sort | modern approaches to glioblastoma therapy |
| topic | glioblastoma nanoparticles immunotherapy small-molecule inhibitors |
| url | https://www.cancersp.com/jour/article/view/192 |
| work_keys_str_mv | AT nskuznetsova modernapproachestoglioblastomatherapy AT svgurova modernapproachestoglioblastomatherapy AT asgoncharova modernapproachestoglioblastomatherapy AT evzaikina modernapproachestoglioblastomatherapy AT magusareva modernapproachestoglioblastomatherapy AT mszinkovich modernapproachestoglioblastomatherapy |